Latest News and Press Releases

HCW Biologics Granted Extension by Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In- Human Phase 1 Clinical Trial

Dr. Hing C. Wong will speak at Genscript conference on January 15, 2025.

Mandatory press release to disclose receipt of Nasdaq Staff Determination Letter.

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

HCW Biologics signed license agreement with WY Biotech

Press release for Q3 2024 business highlights and financial results

Results of Q2 2024, including settlement of long-running arbitration.

Results of Q2 2024, including settlement of long-running arbitration.

Earning release for Q1 2024